- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05904743
INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes
INHALE-3: A 17-Week Randomized Trial and a 13-Week Extension, Evaluating the Efficacy and Safety of Inhaled Insulin (Afrezza) Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Jennifer Pleitez
- Phone Number: (818) 661-5000
- Email: EndocrineResearch@mannkindcorp.com
Study Contact Backup
- Name: Johanna Ulloa
- Phone Number: (818) 661-5000
- Email: EndocrineResearch@mannkindcorp.com
Study Locations
-
-
California
-
Loma Linda, California, United States, 92354
- Loma Linda University-Diabetes Treatment Center
-
Santa Barbara, California, United States, 93105
- Sansum Diabetes Research
-
Principal Investigator:
- Kristin Castorino, D.O.
-
Contact:
- Brandon Cobb
- Email: bcobb@sansum.org
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Barbara Davis Center
-
Principal Investigator:
- Halis Akturk, MD
-
Contact:
- Christie Beatson
- Email: CHRISTIE.BEATSON@CUANSCHUTZ.EDU
-
-
Georgia
-
Atlanta, Georgia, United States, 30318
- Atlanta Diabetes Associates
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University Division of Endocrinology, Metabolism and Molecular Medicine
-
Principal Investigator:
- Grazia Aleppo, MD
-
Contact:
- Stefanie Herrmann
- Email: s-herrmann@northwestern.edu
-
-
Iowa
-
West Des Moines, Iowa, United States, 50265
- Iowa Diabetes Research
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
- Boston Medical Center
-
Principal Investigator:
- Devin Steenkamp, MD
-
Contact:
- Astrid Atakov Castillo
- Email: astrid.atakovcastillo@bmc.org
-
Boston, Massachusetts, United States, 02215
- Joslin Diabetes Center
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
Contact:
- Corey Reid
- Email: reid.corey@mayo.edu
-
Principal Investigator:
- Yogish Kudva, MD
-
-
Nevada
-
Henderson, Nevada, United States, 89074
- Las Vegas Endocrinology
-
-
New York
-
Long Island City, New York, United States, 11106
- Endocrine Associate of West Village, PC
-
Contact:
- Jamie Hyatt
- Email: jhyatt@endocrinenyc.com
-
Principal Investigator:
- Anastosios Manessis, MD
-
New York, New York, United States, 10075
- Mount Sinai Diabetes Center
-
Contact:
- Denisa Tamarez
- Email: denisa.tamaraz@mssm.edu
-
Principal Investigator:
- Carol J. Levy, MD
-
Syracuse, New York, United States, 13210
- SUNY Upstate Medical University
-
Contact:
- Susan Bzdick
- Email: bzdicks@upstate.edu
-
Principal Investigator:
- Ruth S. Weinstock, MD,PhD
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- University of North Carolina At Chapel Hill
-
Contact:
- Cassandra Donahue
- Email: cassandra_donahue@med.unc.edu
-
Principal Investigator:
- Jamie Diner, FNP-C
-
-
Texas
-
Austin, Texas, United States, 78731
- Texas Diabetes & Endocrinology, P.A.
-
Principal Investigator:
- Thomas Blevins, MD
-
Contact:
- Chloe Armstrong
- Email: carmstrong@texasdiabetes.com
-
Dallas, Texas, United States, 75390
- The University of Texas Southwestern Medical Center
-
Principal Investigator:
- Philip Raskin, MD
-
Contact:
- Lin Jordan
- Email: Lin.Fan@UTSouthwestern.edu
-
San Antonio, Texas, United States, 78229
- Diabetes and Glandular Disease Clinic, P.A.
-
Principal Investigator:
- Mark Kipnes, MD
-
Contact:
- Candace Faye
- Email: Candace.faye@dgdclinic.com
-
-
Washington
-
Seattle, Washington, United States, 98119
- University of Washington Diabetes Institute
-
Contact:
- Jesica Baran
- Email: jbaran@uw.edu
-
Principal Investigator:
- Irl B. Hirsch, MD
-
-
West Virginia
-
Parkersburg, West Virginia, United States, 26101
- Mountain State Diabetes
-
Contact:
- Dana Cruse, CNP
- Email: dcruse@mountainstatediabetes.com
-
Principal Investigator:
- David Pickering, DO
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ability to provide informed consent for study participation
- Clinical diagnosis of T1D (per the Investigator)
- Treatment with insulin for at least 6 months prior to the collection of the baseline continuous glucose monitoring (CGM) data
Same treatment regimen (MDI, an AID system, or an insulin pump without automation) for the 3 months prior to screening
- Current (at time of screening) rapid-acting insulin analog (RAA) in use for at least 4 weeks
- If AID system used, automated insulin delivery must be active >85% of the time in the 4 weeks prior to screening
- If MDI used, participant must be using a long-acting basal insulin plus injecting a RAA bolus for meals, per Investigator
- Total daily insulin dose 20-100 units
- Age ≥ 18 years
- HbA1c <11.0%
- Participant uses real-time CGM (any type of real-time CGM) on a regular basis (at least 70% of the time in the 4 weeks prior to screening)
- No use of inhaled insulin in the 3 months prior to screening
- If female of childbearing potential, willing and able to have pregnancy testing
- Investigator believes that the participant can safely use the study treatment and will follow protocol
No medical, psychiatric,or other conditions, or medications being taken that in the Investigator's judgement would be a safety concern for participation in the study
- This includes considering the potential impact of medical conditions known to be present including cardiovascular, liver, kidney disease, thyroid disease, adrenal disease, malignancies, vision difficulties, active proliferative retinopathy, and other medical conditions; psychiatric conditions including eating disorders; drug or alcohol abuse.
Exclusion Criteria:
- History of recent blood transfusions (within previous 3 months prior to randomization), hemoglobinopathies, (sickle cell trait is not an exclusion), or any other conditions that affect HbA1c measurements
- Recent history of asthma (defined as using any medications to treat within the last year), chronic obstructive pulmonary disease (COPD), or any other clinically important pulmonary disease (e.g., cystic fibrosis or bronchopulmonary dysplasia), or significant congenital or acquired cardiopulmonary disease as judged by the Investigator
- Exposure to any investigational product(s), including drugs or devices, in the 90 days prior to the start of screening
- Any disease other than diabetes or current use (or anticipated use during the study) of any medication that, in the judgment of the Investigator, may impact glucose metabolism
- Current or anticipated acute uses of oral, inhaled or injectable glucocorticoids during the time period of the trial (topical glucocorticoid use is acceptable)
- Use of a non-insulin glucose-lowering medication within 3 months prior to signing informed consent
- Smoking (includes cigarettes, cigars, pipes, marijuana, and vaping devices) within 3 months prior to screening
- Pregnant or lactating, planning to become pregnant during the study, or is a woman of childbearing potential and not on an acceptable form of birth control (acceptable includes abstinence, condoms, oral/injectable contraceptives, IUD, or implant); childbearing means that menstruation has started, and the participant is not surgically sterile or greater than 12 months post-menopausal
- No known stage 4/5 renal failure or on dialysis
- Taking Hydroxyurea medication
- An event of severe hypoglycemia, as judged by the Investigator, within the last 90 days prior to screening
- An episode of diabetic ketoacidosis (DKA) diagnosed at a health care facility within the 90 days prior to screening or severe hypoglycemia event within the 90 days prior to screening
- Employed by, or having immediate family members employed by MannKind Corporation or JAEB Center for Health Research, or having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as Study Investigator, coordinator, etc.); or having a first-degree relative who is directly involved in in conducting the clinical trial
- Have a history or current diagnosis of lung cancer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Afrezza (Technosphere Insulin) + insulin degludec
The Afrezza-Degludec group will inhale Afrezza at meals and corrections and will inject insulin degludec once a day for the 17 weeks of the RCT Phase.
Dexcom CGM will be provided.
The Afrezza-Degludec group will continue to use Afrezza and insulin degludec for an additional 13 weeks in the Extension Phase.
|
Pharmaceutical form: powder Route of administration: inhalation
Other Names:
Pharmaceutical form: solution for injection Route of administration: subcutaneous
|
Active Comparator: Usual Care: Insulin delivery with either MDI, a pump without automation, or an AID system and CGM
The Usual Care group will continue to receive insulin as they did before the study.
This could be by injections or by using an insulin pump with or without automation for the 17 weeks of the RCT Phase.
Participants will continue to use their personal CGM as they did before the study.
The Usual Care group will then use Afrezza and insulin degludec for 13 weeks in the Extension Phase.
Dexcom CGM will be provided during the Extension Phase.
|
Pharmaceutical form: clear and colorless solution for injection Route of administration: subcutaneous
Other Names:
Pharmaceutical form: clear and colorless solution for injection Route of administration: subcutaneous
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in HbA1c
Time Frame: 17 weeks
|
Change in HbA1c from baseline to 17 weeks (non-inferiority, non-inferiority margin 0.4%)
|
17 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CGM-measured percent time with glucose <54 mg/dL
Time Frame: 17 weeks
|
CGM-measured percent time with glucose <54 mg/dL from baseline to 17 weeks (non-inferiority, margin 0.5%)
|
17 weeks
|
CGM-measured percent time with glucose <70 mg/dL
Time Frame: 17 weeks
|
CGM-measured percent time with glucose <70mg/dL from baseline to 17 weeks (non-inferiority, margin 2.0%)
|
17 weeks
|
CGM-measured daytime (0600-midnight) percent time in range with glucose 70-180 mg/dL
Time Frame: 17 weeks
|
CGM-measured daytime (0600-midnight) percent time in range with glucose 70-180 mg/dL from baseline to 17 weeks, for superiority assessment
|
17 weeks
|
Mean CGM glucose
Time Frame: 17 weeks
|
Mean CGM glucose from baseline to 17 weeks, for superiority assessment
|
17 weeks
|
CGM-measured (24-hours) percent time in range with glucose 70-180 mg/dL
Time Frame: 17 weeks
|
CGM-measured (24-hours) percent time in range with glucose 70-180 mg/dL from baseline to 17 weeks, for superiority assessment
|
17 weeks
|
CGM-measured percent time with glucose >180 mg/dL
Time Frame: 17 weeks
|
CGM-measured percent time with glucose > 180 mg/dL from baseline to 17 weeks, for superiority assessment
|
17 weeks
|
HbA1c
Time Frame: 17 weeks
|
HbA1c from baseline to 17 weeks, for superiority assessment
|
17 weeks
|
CGM-measured time with glucose >250 mg/dL
Time Frame: 17 weeks
|
CGM-measured time with glucose >250 mg/dL from baseline to 17 weeks, for superiority assessment
|
17 weeks
|
CGM-measured time with glucose <70 mg/dL
Time Frame: 17 weeks
|
CGM-measured time with glucose <70 mg/dL from baseline to 17 weeks, for superiority assessment
|
17 weeks
|
CGM-measured time with glucose <54 mg/dL
Time Frame: 17 weeks
|
CGM-measured time with glucose <54 mg/dL from baseline to 17 weeks, for superiority assessment
|
17 weeks
|
CGM-measured coefficient of variation
Time Frame: 17 weeks
|
CGM-measured coefficient of variation from baseline to 17 weeks, for superiority assessment
|
17 weeks
|
Incidence of severe hypoglycemia events
Time Frame: 30 weeks
|
Incidence of severe hypoclycemia events, defined as events requiring assistance of another person due to cognitive impairment to actively administer carbohydrate, glucagon, or other resuscitative actions
|
30 weeks
|
CGM-measured percent time with glucose <54 mg/dL
Time Frame: 30 weeks
|
CGM-measured percent time with glucose <54 mg/dL
|
30 weeks
|
Other serious adverse events, including hospitalizations
Time Frame: 30 weeks
|
Other serious adverse events, including hospitalizations
|
30 weeks
|
Incidence and severity of treatment-emergent adverse events (TEAEs)
Time Frame: 30 weeks
|
Incidence and severity of treatment-emergent adverse events (TEAEs)
|
30 weeks
|
Incidence and severity of adverse events of special interest (AESIs) as well as the number of participants with AESIs and number of individual events
Time Frame: 30 weeks
|
Incidence and severity of adverse events of special interest (AESIs) as well as the number of participants with AESIs and number of individual events
|
30 weeks
|
Change from baseline to 17 weeks in FEV1
Time Frame: 17 weeks
|
Change from baseline to 17 weeks in FEV1
|
17 weeks
|
Proportions of participants in each group who have experienced ≥20% reduction in FEV1 from baseline to Week 17
Time Frame: 30 weeks
|
Proportions of participants in each group who have experienced ≥20% reduction in FEV1 from baseline to Week 17
|
30 weeks
|
Hypoglycemic events from logged BGM measurements: Level 1 events (<70 mg/dL) and Level 2 events (<54 mg/dL) separately
Time Frame: 30 weeks
|
Hypoglycemic events from logged BGM measurements: Level 1 events (<70 mg/dL) and Level 2 events (<54 mg/dL)
|
30 weeks
|
Hyperglycemic events from logged BGM measurements
Time Frame: 30 weeks
|
Hyperglycemic events from logged BGM measurements
|
30 weeks
|
CGM-measured prolonged hyperglycemia events
Time Frame: 30 weeks
|
CGM-measured prolonged hyperglycemia events
|
30 weeks
|
CGM-measured hypoglycemia events (both a safety and efficacy endpoint)
Time Frame: 17 weeks
|
CGM-measured hypoglycemia events (both a safety and efficacy endpoint)
|
17 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weight
Time Frame: 17 weeks
|
Weight
|
17 weeks
|
Post prandial glucose for first meal challenge
Time Frame: 17 weeks
|
Post prandial glucose for first meal challenge
|
17 weeks
|
Area under the curve (AUC) for first meal challenge
Time Frame: 17 weeks
|
Area under the curve (AUC) for first meal challenge
|
17 weeks
|
Patient-reported outcome (PRO) questionnaires
Time Frame: 17 weeks
|
Type 1 Diabetes Distress Scale (T1-DDS): 28-item validated survey pertaining to distress symptoms related to diabetes (recorded from a scale of 1 to 6). Hypoglycemia Confidence Scale (HCS): 9-item validated survey pertaining to situations where hypoglycemia could occur and queries about the participant's level of confidence in those situations (recorded from a scale 1 to 4). Insulin Treatment Satisfaction Questionnaire (ITSQ): 22-item survey with a 5-factor structure assessing insulin satisfaction (scores range from 0 to 100). Freedom and Flexibility: 6-item non-validated survey pertaining to life experiences impacted by having diabetes (scores range from 6 to 36) Insulin Adherence: 1-item non-validated survey pertaining to number of missed boluses in the past week |
17 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Kevin Kaiserman, MD, Mannkind Corporation
- Study Chair: Irl B. Hirsch, MD, University of Washington
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MKC-TI-193
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 1
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute of Biocybernetics...UnknownType 1 Diabetes Mellitus With Hyperglycemia | Type 1 Diabetes Mellitus With HypoglycaemiaPoland
Clinical Trials on Afrezza
-
Mannkind CorporationCompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1United States
-
Model Clinical Research LLCMannkind CorporationCompletedType2 DiabetesUnited States
-
Yale UniversityCompletedPost-Prandial Hyperglycemia | Post-Prandial HypoglycemiaUnited States
-
Mannkind CorporationCompleted
-
Mannkind CorporationCompletedType 1 Diabetes MellitusUnited States
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Asthma | Type 1 Diabetes Mellitus | Moderate Chronic Obstructive Pulmonary DiseaseUnited States, Russian Federation, Ukraine
-
Mannkind CorporationNo longer availableType 1 Diabetes | Type 2 DiabetesUnited States
-
Diabetes and Glandular Disease ClinicMannkind Corporation; DexCom, Inc.UnknownType 2 Diabetes Treated With InsulinUnited States
-
Informed Data Systems, Inc.Mannkind CorporationUnknownDiabetes Mellitus, Type 2United States
-
Mannkind CorporationCompleted